Aimovig®▼ in the real world

Webinar:  January 21st 2021, 6.30pm

Speaker: Professor. Stewart Tepper

 

 

▼This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: drugsafety.dublin@novartis.com or by calling 01 2080 612.

 Legal Category: POM Marketing Authorisation Holder: Novartis Europharm Ltd, Vista Building, Elm Park,Merrion Road, Dublin 4, Ireland Marketing Authorisation Numbers: EU/1/18/1293/001-006 Full prescribing information is available upon request from: Novartis Ireland Limited, Vista Building, Elm Park Business Campus, Merrion Road, Dublin 4 Ireland, Tel: + 353 1 220 4100 or at www.medicines.ie